Viage
San Francisco Bay Area, US · 4 known investors
Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease. Its pipeline includes neuropeptides and small molecules aimed at cognitive impairment, depression, anxiety, and inflammatory disease.
Founders & leadership
Investors · 4
Frequently asked questions
- What does Viage do?
- Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease. Its pipeline includes neuropeptides and small molecules aimed at cognitive impairment, depression, anxiety, and inflammatory disease.
- Who are Viage's investors?
- Viage's investors include Kyoto University Innovation Capital, Miyako Capital, RDiscovery, Remiges Ventures, Inc..
- Where is Viage headquartered?
- Viage is headquartered in San Francisco Bay Area, US.